The historical data trend for Zymeworks's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZYME vs SRPT, BCAX, INVA: Buyback Yield % Comparison
For the Biotechnology subindustry, Zymeworks's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zymeworks Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zymeworks's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Zymeworks's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zymeworks (ZYME) has a Buyback Yield % of -8.84 as of Jul. 08, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Zymeworks and its competitors. According to the industry distribution chart, Zymeworks ranks #377 out of 741 companies in the Biotechnology industry, placing it in the top 50.9%.
Is Zymeworks' Buyback Yield % too high?
Zymeworks' current Buyback Yield % is -8.84. Based on the distribution chart, Zymeworks ranks #377 out of 741 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Zymeworks has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zymeworks' Buyback Yield % compare to SRPT and BCAX?
According to the Biotechnology industry distribution chart, Zymeworks ranks #377 out of 741 companies for Buyback Yield %. This places Zymeworks in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Zymeworks and its competitors. Zymeworks's current Buyback Yield % is -8.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zymeworks stock overvalued right now?
Based on GuruFocus' analysis, Zymeworks (ZYME) is currently considered Fairly Valued. The stock's GF Value™ is $24.72, compared to a current price of $26.65 — trading 7.8% above its estimated fair value. The current Buyback Yield % is -8.84. Zymeworks' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Zymeworks (ZYME), the current Buyback Yield % is -8.84 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zymeworks (ZYME) Overvalued in 2026?
Based on GuruFocus' analysis, Zymeworks stock appears to be overvalued.
The current stock price of $26.65 is trading 7.8% above its estimated GF Value™ of $24.72.
GuruFocus considers Zymeworks to be Fairly Valued.
Key valuation signals for ZYME:
Buyback Yield %: -8.84
GF Value™: $24.72 vs. price of $26.65 (7.8% above fair value)
No single metric tells the full story. See the ZYME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
66GF Score
Get the complete analysis for ZYME
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZYME has been successfully added to your 
